Artificial Pancreas
At JDRF’s Artificial Pancreas Program, we are working to provide technology that is small, user-friendly and accurate, so that people with type 1 diabetes (T1D) can get through the day without needing to check blood-sugar levels or dose insulin as often.
Our Approach
In people with T1D, the body often defies even the most vigilant efforts to keep blood-sugar levels normal. Artificial pancreas systems, however, take over much of the blood-sugar management. They monitor blood-glucose levels with a continuous glucose monitor (CGM) and use an algorithm to automatically provide the right amount of insulin at the right time—much like a normal pancreas would do naturally.
-
![]()
Create miniaturized devices
-
![]()
Enable open systems
-
![]()
Drive algorithm advancements
Many Paths, One Purpose
Our research into artificial pancreas devices and technologies is just one potential pathway to finding a cure for T1D. Explore JDRF’s ambitious research portfolio.
All ResearchGet involved and help lead us toward a cure
Artificial Pancreas Progress
2017
Anthem decides to cover artificial pancreas systems
JDRF’s Coverage2Control campaign convinces America’s second-largest health insurance company, to cover the artificial pancreas systems.
2018
JDRF and SFC partner for open protocol designs
JDRF announces funding for SFC Fluidics to develop an insulin patch pump with open protocol communication capabilities.
2018
JDRF partners to develop AID Systems
JDRF and Ypsomed, a Switzerland-based developer and manufacturer of injection and infusion systems, partnere as part of JDRF’s Open Protocol Automated Insulin Delivery (AID) Systems Initiative.
2019
FDA Authorizes a Second Artificial Pancreas System
The FDA authorized an algorithm that enables the second artificial pancreas system: The Control-IQ™ advanced hybrid closed loop technology.
Looking Ahead
To date, more than $110 million has been invested by JDRF. Future research will continue to automate blood-sugar management, dramatically reduce T1D-related risks and reduce the burden on people living with the disease.